Bellevue Life Sciences Acquisition - Tradeable Rights - Feb 2028 Operating Income

As of the most recent data (June 2026), BLACR shows a operating income of $-17M. That compares with $-11M in the prior-year period — down 57.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BLACR's operating income is now $-17M (was $-11M) — a 57.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Bellevue Life Sciences Acquisition - Tradeable Rights - Feb 2028 is outperforming or lagging.

Tracking BLACR's operating income over time shows whether Bellevue Life Sciences Acquisition - Tradeable Rights - Feb 2028 is scaling, shrinking, or reshaping that part of the business. The current reading is $-17M That compares with $-11M in the prior-year period — down 57.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has Bellevue Life Sciences Acquisition - Tradeable Rights - Feb 2028's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-17M) with ownership activity and broader fundamentals.